Nothing Special   »   [go: up one dir, main page]

GT199900102A - Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen. - Google Patents

Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.

Info

Publication number
GT199900102A
GT199900102A GT199900102A GT199900102A GT199900102A GT 199900102 A GT199900102 A GT 199900102A GT 199900102 A GT199900102 A GT 199900102A GT 199900102 A GT199900102 A GT 199900102A GT 199900102 A GT199900102 A GT 199900102A
Authority
GT
Guatemala
Prior art keywords
procedure
preparation
pharmaceutical compositions
phenoxipropanolamines
contain
Prior art date
Application number
GT199900102A
Other languages
English (en)
Inventor
Roberto Cecchi
Tiziano Croci
Umberto Guzzi
Eric Marsault
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT199900102A publication Critical patent/GT199900102A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/40—Radicals substituted by oxygen atoms
    • C07D307/42—Singly bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCIÒN SE REFIERE A NUEVAS FENOXIPROPANOLAMINAS, A LAS COMPOSICIONES FARMACÈUTICAS QUE LAS CONTIENEN, A UN PROCEDIMIENTO PARA SU PREPARACIÒN Y LOS INTERMEDIARIOS EN ESTE PROCEDIMIENTO.
GT199900102A 1998-06-18 1999-07-01 Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen. GT199900102A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9807660A FR2780057B1 (fr) 1998-06-18 1998-06-18 Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant

Publications (1)

Publication Number Publication Date
GT199900102A true GT199900102A (es) 2000-12-22

Family

ID=9527517

Family Applications (1)

Application Number Title Priority Date Filing Date
GT199900102A GT199900102A (es) 1998-06-18 1999-07-01 Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.

Country Status (12)

Country Link
US (1) US6649627B1 (es)
EP (1) EP1087961B1 (es)
JP (1) JP4563581B2 (es)
AR (1) AR018639A1 (es)
AT (1) ATE222250T1 (es)
AU (1) AU4048299A (es)
CO (1) CO5011052A1 (es)
DE (1) DE69902535T2 (es)
ES (1) ES2183557T3 (es)
FR (1) FR2780057B1 (es)
GT (1) GT199900102A (es)
WO (1) WO1999065895A1 (es)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9902987D0 (sv) 1999-08-24 1999-08-24 Astra Pharma Prod Novel compounds
DE60033964T2 (de) 1999-12-17 2007-11-29 Sanofi-Aventis Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung
FR2802533B1 (fr) 1999-12-17 2002-02-15 Sanofi Synthelabo Phenoxypropanolamines, leur preparation et leur application en therapeutique
CO5300399A1 (es) 2000-02-25 2003-07-31 Astrazeneca Ab Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen
US6753322B2 (en) 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US7005439B2 (en) 2000-06-20 2006-02-28 Astrazeneca Ab Compounds
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
KR20030016396A (ko) * 2000-07-13 2003-02-26 일라이 릴리 앤드 캄파니 베타３ 아드레날린 효현제
US6525202B2 (en) 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
US6451814B1 (en) 2000-07-17 2002-09-17 Wyeth Heterocyclic β-3 adrenergic receptor agonists
US6465501B2 (en) 2000-07-17 2002-10-15 Wyeth Azolidines as β3 adrenergic receptor agonists
US6514991B2 (en) 2000-07-17 2003-02-04 Wyeth Phenyl-oxo-tetrahydroquinolin-3-yl beta-3 adrenergic receptor agonists
US6410734B1 (en) 2000-07-17 2002-06-25 Wyeth 2-substituted thiazolidinones as beta-3 adrenergic receptor agonists
US6395762B1 (en) 2000-07-17 2002-05-28 American Home Products Corporation Phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
US6537994B2 (en) 2000-07-17 2003-03-25 Wyeth Heterocyclic β3 adrenergic receptor agonists
US6444685B1 (en) * 2000-07-17 2002-09-03 Wyeth N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists
US6458817B1 (en) 2000-07-17 2002-10-01 Wyeth Substituted arylsulfides, arylsulfoxides and arylsulfones as beta-3 adrenergic receptor agonists
US6498170B2 (en) 2000-07-17 2002-12-24 Wyeth Cyclamine sulfonamides as β-3 adrenergic receptor agonists
US6506901B2 (en) * 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists
US6509358B2 (en) 2000-07-17 2003-01-21 Wyeth Piperidino-phenyl amino squarate and thiadiazole dioxide beta-3 adrenergic receptor agonists
FR2817257B1 (fr) * 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
GB0104050D0 (en) 2001-02-19 2001-04-04 Astrazeneca Ab Chemical compounds
AR035230A1 (es) 2001-03-19 2004-05-05 Astrazeneca Ab Compuestos de bencimidazol, proceso para su preparacion, composicion farmaceutica, proceso para la preparacion de dicha composicion farmaceutica, y usos de estos compuestos para la elaboracion de medicamentos
GB0107228D0 (en) 2001-03-22 2001-05-16 Astrazeneca Ab Chemical compounds
SE0101038D0 (sv) * 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
SE0103818D0 (sv) 2001-11-15 2001-11-15 Astrazeneca Ab Chemical compounds
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
FR2840301B1 (fr) * 2002-05-29 2007-03-23 Sanofi Synthelabo Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
EP1909973B1 (en) 2005-07-15 2018-08-22 Micell Technologies, Inc. Polymer coatings containing drug powder of controlled morphology
WO2007011708A2 (en) 2005-07-15 2007-01-25 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
PE20080361A1 (es) 2006-04-21 2008-06-03 Novartis Ag Compuestos derivados de purina como activadores del receptor de adenosina a2a
CA2650590C (en) 2006-04-26 2018-04-03 Micell Technologies, Inc. Coatings containing multiple drugs
US8636767B2 (en) 2006-10-02 2014-01-28 Micell Technologies, Inc. Surgical sutures having increased strength
CN101678388B (zh) 2006-10-23 2013-12-11 米歇尔技术公司 用于在涂覆过程中为基底充电的保持器
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
WO2008086369A1 (en) 2007-01-08 2008-07-17 Micell Technologies, Inc. Stents having biodegradable layers
EP1947103A1 (en) 2007-01-22 2008-07-23 4Sc Ag Aryloxypropanolamines, methods of preparation thereof and use of aryloxypropanolamines as medicaments
CA2688314C (en) 2007-05-25 2013-12-03 Micell Technologies, Inc. Polymer films for medical device coating
NZ588549A (en) 2008-04-17 2013-05-31 Micell Technologies Inc Stents having bioabsorbable layers
JP2011528275A (ja) 2008-07-17 2011-11-17 ミセル テクノロジーズ，インク． 薬物送達医療デバイス
US9510856B2 (en) 2008-07-17 2016-12-06 Micell Technologies, Inc. Drug delivery medical device
US8834913B2 (en) 2008-12-26 2014-09-16 Battelle Memorial Institute Medical implants and methods of making medical implants
CN102481195B (zh) 2009-04-01 2015-03-25 米歇尔技术公司 涂覆支架
EP2419058B1 (en) 2009-04-17 2018-02-28 Micell Technologies, Inc. Stents having controlled elution
WO2011097103A1 (en) 2010-02-02 2011-08-11 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
US8795762B2 (en) 2010-03-26 2014-08-05 Battelle Memorial Institute System and method for enhanced electrostatic deposition and surface coatings
CA2797110C (en) 2010-04-22 2020-07-21 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
CA2805631C (en) 2010-07-16 2018-07-31 Micell Technologies, Inc. Drug delivery medical device
WO2012166819A1 (en) 2011-05-31 2012-12-06 Micell Technologies, Inc. System and process for formation of a time-released, drug-eluting transferable coating
US10117972B2 (en) 2011-07-15 2018-11-06 Micell Technologies, Inc. Drug delivery medical device
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
KR20150143476A (ko) 2013-03-12 2015-12-23 미셀 테크놀로지즈, 인코포레이티드 생흡수성 생체의학적 임플란트
WO2014186532A1 (en) 2013-05-15 2014-11-20 Micell Technologies, Inc. Bioabsorbable biomedical implants
MA44037B1 (fr) 2016-06-06 2020-03-31 Arena Pharm Inc Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
NZ748072A (en) 2017-03-20 2020-06-26 Forma Therapeutics Inc Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators
EP3852791B1 (en) 2018-09-19 2024-07-03 Novo Nordisk Health Care AG Activating pyruvate kinase r
BR112021005188A2 (pt) 2018-09-19 2021-06-08 Forma Therapeutics, Inc. tratamento de anemia falciforme com um composto de ativação de piruvato cinase r
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI76551C (fi) * 1980-11-06 1988-11-10 Sandoz Ag Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 3-aminopropoxifenylderivat.
GB2163150B (en) * 1984-07-19 1988-05-25 Sandoz Ltd 3-aminopropoxyaryl derivatives
US5145967A (en) * 1989-04-20 1992-09-08 Anaquest, Inc. Method for preparing 4-alkoxyalkyl-4-phenylaminopiperdines and derivatives thereof
CA2068523A1 (en) 1989-11-21 1991-05-22 Augustinus Gregorius Henricus Meijers Thermoplastic saddle in two parts for repairing or renovating a pipeline with branch pipe and repaired or renovated pipe with a saddle
MY110227A (en) * 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
GB9318431D0 (en) * 1993-09-06 1993-10-20 Boots Co Plc Therapeutic agents

Also Published As

Publication number Publication date
US6649627B1 (en) 2003-11-18
EP1087961B1 (fr) 2002-08-14
FR2780057A1 (fr) 1999-12-24
JP4563581B2 (ja) 2010-10-13
AU4048299A (en) 2000-01-05
ES2183557T3 (es) 2003-03-16
FR2780057B1 (fr) 2002-09-13
DE69902535T2 (de) 2003-04-10
JP2002518385A (ja) 2002-06-25
CO5011052A1 (es) 2001-02-28
DE69902535D1 (de) 2002-09-19
WO1999065895A1 (fr) 1999-12-23
EP1087961A1 (fr) 2001-04-04
AR018639A1 (es) 2001-11-28
ATE222250T1 (de) 2002-08-15

Similar Documents

Publication Publication Date Title
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
AR005703A1 (es) Oxazolidinonas sustituidas, procedimiento para su preparacion, uso de las mismas para preparar medicamentos y medicamentos que las contienen
MX9102501A (es) Derivados de metano sulfonamida, composiciones farderivados de metanosulfonamida, composiciones farmaceuticas que los contienen y procedimiento para smaceuticas que los contienen y procedimiento para u preparacion. su preparacion.
AR240810A1 (es) 1-azolil-2-aril 3-fluoralcan-2-oles utiles como microbicidas, procedimiento para su preparacion, composiciones que los contienen e intermediarios.
MX9202289A (es) Nuevos derivados de tiopiranopirrol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
MX9206306A (es) Peptidos, procedimiento para su produccion y composicion farmaceutica que los contiene.
MX9200324A (es) Nuevos esteroides, procedimiento para su preparacinuevos esteroides, procedimiento para su preparacion y composicion farmaceutica que los contiene. on y composicion farmaceutica que los contiene.
MX9102500A (es) Compuestos de bifenilio, procedimiento para su preparacion y composicion farmaceutica que los contiene.
MX9207383A (es) Derivados de 2-imidazolin-5-onas y 2-imidazolin-5-tionas, procedimiento para su preparacion y composiciones fungicidas que los contienen.
MX9102580A (es) Nuevas benzodiacepinonas, procedimiento para su preparacion y composicion farmaceutica que las contiene.
MX9200731A (es) Compuestos de hidrazona, procedimientos para su prcompuestos de hidrazona, procedimientos para su preparacion, compuestos intermedios utiles para su oeparacion, compuestos intermedios utiles para suobtencion y composiciones pesticidas que contienena btencion y composiciones pesticidas que contienenalos mismos. los mismos.
PA8469101A1 (es) Ligandos azabiciclicos de receptores 5ht1
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
UY25357A1 (es) Nuevos pentasacáridos, procedimiento para su preparación y composiciones farmacéuticas que los contienen.
AR002017A1 (es) Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento.
HN1999000196A (es) Derivados de indol
ES2186989T3 (es) Cristales de maltitol de formas especificas, compuestos cristalinos que los contienen y procedimientos para su preparacion.
MX9204395A (es) Derivados de 3-desoxi-manosamina, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ES2179529T3 (es) Compuestos biaromaticos unidos por un radical heteroetinileno, y composiciones farmaceuticas y cosmeticas que los contienen.
ES2174297T3 (es) Nuevos derivados de piranosidos.
HN2000000056A (es) Nuevas formas cristalinas de un antibiotico macrolido
MX6424A (es) Derivados de tripeptidos, procedimientos para la preparacion de derivados de tripeptidos y composiciones que los contienen.
MX9207269A (es) Bencimidazoles substituidos, proceso para su preparacion y composiciones farmaceuticas que los contienen.
MX9206516A (es) Parasiticidas de formazano, proceso para su preparacion y composicion parasiticida que los contiene.
AR024282A1 (es) Compuestos derivdos de piperidin-etanosulfonil, su empleo, procedimiento para prepararlos y medicamentos que los contienen